205 related articles for article (PubMed ID: 32588428)
1. Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome.
Kawata E; Lazo-Langner A; Xenocostas A; Hsia CC; Howson-Jan K; Deotare U; Saini L; Yang P; Broadbent R; Levy M; Howlett C; Stuart A; Kerkhof J; Santos S; Lin H; Sadikovic B; Chin-Yee I
Br J Haematol; 2021 Feb; 192(4):729-736. PubMed ID: 32588428
[TBL] [Abstract][Full Text] [Related]
2. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
3. Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes.
Qin Y; Zhang H; Feng L; Wei H; Wu Y; Jiang C; Xu Z; Zhu H; Liu T
Ann Med; 2022 Dec; 54(1):2627-2636. PubMed ID: 36148999
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data.
Kern W; Haferlach C; Schnittger S; Haferlach T
Cancer; 2010 Oct; 116(19):4549-63. PubMed ID: 20572043
[TBL] [Abstract][Full Text] [Related]
5. Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?
Kawata E; Hedley BD; Chin-Yee B; Xenocostas A; Lazo-Langner A; Hsia CC; Howson-Jan K; Yang P; Levy MA; Santos S; Bhai P; Howlett C; Lin H; Kadour M; Sadikovic B; Chin-Yee I
Int J Lab Hematol; 2022 Apr; 44(2):333-341. PubMed ID: 34713980
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of next generation sequencing in myelodysplastic syndromes.
Spaulding TP; Stockton SS; Savona MR
Br J Haematol; 2020 Jan; 188(2):224-239. PubMed ID: 31571207
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
8. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.
Margolskee E; Hasserjian RP; Hassane D; Tam W; Mathew S; Ok CY; Wang SA; Oak J; Arber DA; Orazi A
Am J Clin Pathol; 2017 Jul; 148(1):49-57. PubMed ID: 28927162
[TBL] [Abstract][Full Text] [Related]
10. Getting personal with myelodysplastic syndromes: is now the right time?
Chokr N; Pine AB; Bewersdorf JP; Shallis RM; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Apr; 12(4):215-224. PubMed ID: 30977414
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
Mecucci C
Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).
Yun S; Geyer SM; Komrokji RS; Al Ali NH; Song J; Hussaini M; Sweet KL; Lancet JE; List AF; Padron E; Sallman DA
Leukemia; 2021 Apr; 35(4):1145-1155. PubMed ID: 32728186
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.
Siddon AJ; Weinberg OK
Clin Lab Med; 2023 Dec; 43(4):607-614. PubMed ID: 37865506
[TBL] [Abstract][Full Text] [Related]
14. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
15. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
17. The Dawn of next generation DNA sequencing in myelodysplastic syndromes- experience from Pakistan.
Anwar N; Memon FA; Shahid S; Shakeel M; Irfan M; Arshad A; Naz A; Ujjan ID; Shamsi T
BMC Genomics; 2021 Dec; 22(1):903. PubMed ID: 34915860
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes.
Maurya N; Mohanty P; Dhangar S; Panchal P; Jijina F; Mathan SLP; Shanmukhaiah C; Madkaikar M; Vundinti BR
Sci Rep; 2022 Apr; 12(1):5925. PubMed ID: 35396491
[TBL] [Abstract][Full Text] [Related]
19. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
Hughes CFM; Gallipoli P; Agarwal R
Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic methods in the diagnosis of myelodysplastic syndromes. A review.
Lukackova R; Gerykova Bujalkova M; Majerova L; Mladosievicova B
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):339-45. PubMed ID: 24263214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
